for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Hypera SA

HYPE3.SA

Latest Trade

31.13BRL

Change

-0.18(-0.57%)

Volume

2,755,500

Today's Range

30.75

 - 

31.49

52 Week Range

26.07

 - 

42.80

As of on the Bolsa de Valores do Estado de Sao Paulo ∙ Minimum 15 minute delay

Pricing

Previous Close
31.31
Open
31.30
Volume
2,755,500
3M AVG Volume
76.68
Today's High
31.49
Today's Low
30.75
52 Week High
42.80
52 Week Low
26.07
Shares Out (MIL)
633.12
Market Cap (MIL)
19,829.26
Forward P/E
--
Dividend (Yield %)
3.22

Next Event

Q3 2020 Hypera SA Earnings Release

Latest Developments

More

Brazil drugmaker Hypera's CEO says it will reduce discounts on drugs by year-end

Brazil's Hypera forecasts 2020 net profit of 1.3 bln reais -filing

Takeda Agrees To Divest Select OTC And Non-Core Assets In Latin America To Hypera Pharma For $825 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Hypera SA

Hypera SA, formerly Hypermarcas SA, is a Brazil-based company engaged in the pharmaceuticals sector. The Company’s major business units include Branded Prescription, Consumer Health and Branded Generics. Branded Prescription is present in the main therapeutic classes in Brazil and it operates in the Primary Care segment under the umbrella brand Mantecorp Farmasa. The Branded Prescription unit also acts as Mantecorp Skincare in dermocosmetics, with products recommended by dermatologists. Consumer Health offers non-prescription drugs, with brands such as Apracur, Benegrip, Coristina d, Engov, Epocler and Estomazil, among others. The Consumer Health unit also operates in nutritionals and vitamin supplements, with brands such as Tamarine, Vitasay, Biotonico Fontoura and Zero-Cal. Branded Generics operates under the Neo Quimica brand.

Industry

Biotechnology & Drugs

Contact Info

R Nova Cidade. 404, Vila Olimpia

04.547-070

Brazil

+55.62.38788150

http://www.hyperapharma.com.br/

Executive Leadership

Alvado Stainfeld Link

Chairman of the Board

Breno Toledo Pires de Oliveira

Chief Executive Officer, Member of the Board of Directors

Adalmario Ghovatto Satheler do Couto

Chief Financial Officer, Investor Relations Officer, Business Development Officer

Vivian Karina Trujillo Angiolucci

Chief Operating Officer, Member of the Executive Board

Luiz Eduardo Sales Clavis

Commercial and Marketing Vice President

Key Stats

2.07 mean rating - 15 analysts
Sell
Hold
Buy
Revenue (MM, BRL)

2017

3.6K

2018

3.7K

2019

3.3K

2020(E)

4.1K
EPS (BRL)

2017

1.760

2018

1.790

2019

1.820

2020(E)

1.848
Price To Earnings (TTM)
16.78
Price To Sales (TTM)
5.21
Price To Book (MRQ)
2.19
Price To Cash Flow (TTM)
15.45
Total Debt To Equity (MRQ)
54.02
LT Debt To Equity (MRQ)
46.30
Return on Investment (TTM)
10.14
Return on Equity (TTM)
8.91

Latest News

Latest News

UPDATE 1-Brazil's Hypera says 'irregular payments' will be reimbursed, shares jump

Brazilian drugmaker Hypera Pharma said its co-controlling shareholder will reimburse the company after an internal probe found "irregular payments" made by former executives in connection with a criminal investigation, sending shares more than 8% higher.

Brazil's Hypera says internal probe found $20 mln in 'irregular payments'

Brazilian drugmaker Hypera Pharma on Tuesday said an internal investigation found the company had made at least 110.5 million reais ($20.3 million) in "irregular payments" related to a federal criminal probe, according to a securities filing.

Brazil's Hypera signs deal with Eurofarma to sell 12 drugs for $161 mln-filing

Brazilian pharmaceutical company Hypera SA said on Wednesday it has signed a deal with Eurofarma Laboratorios SA for the sale of a portfolio of 12 products in Argentina, Colombia, Ecuador, Mexico, Panama and Peru for $161 million.

BRIEF-Brazil's Hypera forecasts 2020 net profit of 1.3 bln reais -filing

* BRAZIL'S HYPERA SEES 2020 NET REVENUE OF 4.25 BILLION REAIS TO 4.35 BILLION REAIS -FILING

Brazil's Hypera says to buy Boehringer's Buscopan brand for $319 million

Brazilian pharmaceutical company Hypera SA <HYPE3.SA> said on Wednesday it has agreed to buy Boehringer Ingelheim's Buscopan brand and other assets for 1.3 bln reais ($319 million).

Brazil's EMS, Hypera interested in Boehringer's Buscopan brand- source

Brazilian pharmaceutical company EMS is expected to offer 1.5 billion reais ($357.5 million) to acquire painkiller brand Buscopan from German company Boehringer Ingelheim and its Brazilian rival Hypera SA is also interested in the deal, one source with knowledge of the matter...

Brazil's Hypera controlling shareholder in plea deal talks-report

The controlling shareholder of Brazil's Hypera SA is in initial talks about a plea deal, Brazil's Valor Economico newspaper reported on Wednesday, as the pharmaceutical company continues an internal probe into alleged corruption.

Brazil's Hypera reports Q2 net profit of 278.8 mln reais

Quarterly profit at Hypera SA , Brazil's largest listed producer of over-the-counter medicine, rose 22.3 percent on a yearly basis in the second quarter as revenues increased more than 10 percent due to higher overall sales.

Brazil's Hypera appoints committee to investigate after police raid

Brazilian pharmaceuticals company Hypera SA said on Wednesday that its board had appointed an independent committee to investigate alleged corruption by former executives.

Brazil's Hypera in talks for leniency deal, could pay $540 mln fine -paper

Brazilian pharmaceutical company Hypera SA is in talks to agree to a leniency deal with prosecutors that could include a 2 billion reais ($540 million) fine, newspaper Valor Economico reported on Thursday, an agreement that Hypera denied.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up